靶向CD19的CAR-T细胞治疗自身免疫病患者中的局部免疫效应细胞相关毒性综合征:一项观察性研究
本研究在德国两个中心观察39例接受靶向CD19的CAR-T细胞治疗的自身免疫病患者(20例系统性红斑狼疮、13例系统性硬化症、6例特发性炎性肌病),记录到54例次局部反应并命名为局部免疫效应细胞相关毒性综合征(LICATS),累及30例(77%)患者。LICATS仅发生于B细胞缺乏期,仅累及既往受累器官,以皮肤和肾脏最常见,多为1级,全部无后遗症缓解。
要点
- LICATS累及30例(77%)患者,中位起病时间为输注后10天,中位持续时间11天。
- LICATS仅发生于B细胞缺乏期,且仅累及该自身免疫病既往受累的器官。
- 54例次中1级35例次(65%)、2级16例次(30%)、3级仅3例次,全部无后遗症缓解。
核心结论
- LICATS是接受靶向CD19的CAR-T细胞治疗的自身免疫病患者中的一种新毒性形式,最可能基于对受累器官免疫细胞的清除;其具有自限性、器官特异性,且强度通常较轻。
研究设计与样本
- 观察性研究,纳入德国两个中心任何年龄、接受靶向CD19的CAR-T细胞治疗且随访至少30天的自身免疫病患者,评估CAR-T细胞输注后发生的局部器官特异性反应。
- 2021年3月1日至2024年10月31日共39例自身免疫病患者接受靶向CD19的CAR-T细胞治疗(20例系统性红斑狼疮、13例系统性硬化症、6例特发性炎性肌病)。
- 25例(64%)为女性,14例(36%)为男性,中位年龄36岁(IQR 22-44)。
- 有相关亲身经历者参与了研究设计与实施。
主要发现
- 共记录54例次局部反应,命名为局部免疫效应细胞相关毒性综合征(LICATS),累及30例(77%)患者。
- LICATS中位起病时间为CAR-T细胞输注后10天(IQR 9-21),中位持续时间为11天(5-14)。
- LICATS仅发生于B细胞缺乏期,且仅累及该自身免疫病既往受累的器官。
- 最常受累器官为皮肤(54例次中19例次[35%])和肾脏(12例次[22%])。
- 大多数LICATS为轻度(1级35例次[65%];2级16例次[30%]),仅3例次为3级,所有LICATS均无后遗症缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has advanced treatment strategies for severe autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis, and idiopathic inflammatory myopathy. Data regarding side-effects are mostly generated from patients with malignancies, but little is known about autoimmune disease-specific adverse events. This study aimed to describe autoimmune disease-specific adverse events that occur with CAR T-cell therapy. METHODS: In this observational study, patients of any age with autoimmune disease receiving CD19-targeting CAR T-cell therapy in two centres in Germany with a follow-up of at least 30 days were assessed for local organ-specific reactions occurring after CAR T-cell infusion. Observed reactions were documented according to localisation, time of onset, and duration, and were graded for severity (grade 1: spontaneous resolution; grade 2: glucocorticoid treatment due to symptoms lasting >1 week or presence of relevant inner organ involvement; grade 3: prolonged or new hospitalisation; grade 4: intensive care treatment). People with related lived experience were involved in the study design and implementation. FINDINGS: Between March 1, 2021, and Oct 31, 2024, 39 patients with autoimmune disease were treated with CD19-targeting CAR T cells (20 with SLE, 13 with systemic sclerosis, six with idiopathic inflammatory myopathy). 25 (64%) patients were female and 14 (36%) were male. Median age was 36 years (IQR 22-44). 54 local reactions, which we termed local immune effector cell-associated toxicity syndrome (LICATS), were recorded, affecting 30 (77%) patients with a median time of onset of 10 days (IQR 9-21) from CAR T-cell infusion and a median duration of 11 days (5-14). LICATS exclusively occurred during the B-cell aplasia phase and only involved organs previously affected by the respective autoimmune disease. The most frequently affected organs were the skin (19 [35%] of 54) and the kidneys (12 [22%]). Most cases of LICATS were mild (grade 1: 35 [65%]; grade 2: 16 [30%]). Only three cases were grade 3. All events of LICATS resolved without sequelae. INTERPRETATION: LICATS is a new form of toxicity in patients with autoimmune disease receiving CD19-targeting CAR T-cell therapy, most likely based on the cleansing of immune cells from the affected organs. It is self-limited, organ-specific, and usually mild in its intensity. FUNDING: Deutsche Forschungsgemeinschaft (DFG), German Cancer Aid, Bundesministerium für Bildung und Forschung, European Union, Staedtler Foundation, Lupus Research Alliance, and donations from the Bendel family and the Bleyl family.
引用
- Hagen M, Müller F, Wirsching A, et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 2025. PMID: 40318690. doi:10.1016/S2665-9913(25)00091-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。